Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Company filings are the primary source for understanding what changed inside Boundless Bio, Inc. before the market fully reacts. Review recent BOLD disclosures alongside price history and peer context to identify new risks, accounting changes, strategic updates, capital allocation decisions, and operating details that may affect the intrinsic value case.

Price History

Dividend-adjusted closing price

Events

Change

+129.36%

Period High

$2.60

Period Low

$1.05

Latest

$2.50

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Q32 Bio Inc.

NASDAQ:QTTB

$151.78M

AN2 Therapeutics, Inc.

NASDAQ:ANTX

$136.46M

Rallybio Corporation

NASDAQ:RLYB

$91.06M

What is the latest BOLD filing?

The latest filing shown is 8-K dated Jun 23, 2026.

How many recent filings does BOLD have?

Intrinsic Alpha currently shows 20 recent filings for BOLD.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.